Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury

Liliya M. Yamaleyeva, Nadia K. Guimaraes-Souza, Louis S. Krane, Sigrid Agcaoili, Kenneth Gyabaah, Anthony Atala, Tamer Aboushwareb, James J. Yoo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

New therapeutic strategies for chronic kidney disease (CKD) are necessary to offset the rising incidence of CKD and donor shortage. Erythropoietin (EPO), a cytokine produced by fibroblast-like cells in the kidney, has recently emerged as a renoprotective factor with anti-inflammatory, antioxidant properties. This study (a) determined whether human renal cultures (human primary kidney cells [hPKC]) can be enriched in EPO-positive cells (hPKC(F+)) by using magnetic-bead sorting; (b) characterized hPKC(F+) following cell separation; and (c) established that intrarenal delivery of enriched hPKC(F+) cells would be more beneficial in treatment of renal injury, inflammation, and oxidative stress than unsorted hPKC cultures in a chronic kidney injury model. Fluorescence-activated cell sorting analysis revealed higher expression of EPO (36%) and CD73 (27%) in hPKC(F+) as compared with hPKC. After induction of renal injury, intrarenal delivery of hPKC(F+) or hPKC significantly reduced serum creatinine, interstitial fibrosis in the medulla, and abundance of CD68-positive cells in the cortex and medulla (p <. 05). However, only hPKC(F+) attenuated interstitial fibrosis in the renal cortex and decreased urinary albumin (3.5-fold) and urinary tubular injury marker kidney injury molecule 1 (16-fold). hPKC(F+) also significantly reduced levels of renal cortical monocyte chemotactic protein 1 (1.8-fold) and oxidative DNA marker 8-hydroxy-deoxyguanosine (8-OHdG) (2.4-fold). After 12 weeks, we detected few injected cells, which were localized mostly to the cortical interstitium. Although cell therapy with either hPKC(F+) or hPKC improved renal function, the hPKC(F+) subpopulation provides greater renoprotection, perhaps through attenuation of inflammation and oxidative stress. We conclude that hPKC(F+) may be used as components of cell-based therapies for degenerative kidney diseases.

Original languageEnglish
Pages (from-to)373-383
Number of pages11
JournalStem cells translational medicine
Volume1
Issue number5
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Erythropoietin
Cell Culture Techniques
Kidney
Wounds and Injuries
Chronic Renal Insufficiency
Oxidative Stress
Fibrosis
Inflammation

Keywords

  • Adult stem cells
  • Autologous stem cell transplantation
  • Cell biology
  • Cellular therapy
  • Erythropoietin
  • Renal fibrosis
  • Tissue-specific stem cells

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Medicine(all)

Cite this

Yamaleyeva, L. M., Guimaraes-Souza, N. K., Krane, L. S., Agcaoili, S., Gyabaah, K., Atala, A., ... Yoo, J. J. (2012). Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury. Stem cells translational medicine, 1(5), 373-383. https://doi.org/10.5966/sctm.2011-0048

Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury. / Yamaleyeva, Liliya M.; Guimaraes-Souza, Nadia K.; Krane, Louis S.; Agcaoili, Sigrid; Gyabaah, Kenneth; Atala, Anthony; Aboushwareb, Tamer; Yoo, James J.

In: Stem cells translational medicine, Vol. 1, No. 5, 01.12.2012, p. 373-383.

Research output: Contribution to journalArticle

Yamaleyeva, LM, Guimaraes-Souza, NK, Krane, LS, Agcaoili, S, Gyabaah, K, Atala, A, Aboushwareb, T & Yoo, JJ 2012, 'Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury', Stem cells translational medicine, vol. 1, no. 5, pp. 373-383. https://doi.org/10.5966/sctm.2011-0048
Yamaleyeva, Liliya M. ; Guimaraes-Souza, Nadia K. ; Krane, Louis S. ; Agcaoili, Sigrid ; Gyabaah, Kenneth ; Atala, Anthony ; Aboushwareb, Tamer ; Yoo, James J. / Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury. In: Stem cells translational medicine. 2012 ; Vol. 1, No. 5. pp. 373-383.
@article{9a4558d41a5e4183849ab7012373d893,
title = "Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury",
abstract = "New therapeutic strategies for chronic kidney disease (CKD) are necessary to offset the rising incidence of CKD and donor shortage. Erythropoietin (EPO), a cytokine produced by fibroblast-like cells in the kidney, has recently emerged as a renoprotective factor with anti-inflammatory, antioxidant properties. This study (a) determined whether human renal cultures (human primary kidney cells [hPKC]) can be enriched in EPO-positive cells (hPKC(F+)) by using magnetic-bead sorting; (b) characterized hPKC(F+) following cell separation; and (c) established that intrarenal delivery of enriched hPKC(F+) cells would be more beneficial in treatment of renal injury, inflammation, and oxidative stress than unsorted hPKC cultures in a chronic kidney injury model. Fluorescence-activated cell sorting analysis revealed higher expression of EPO (36{\%}) and CD73 (27{\%}) in hPKC(F+) as compared with hPKC. After induction of renal injury, intrarenal delivery of hPKC(F+) or hPKC significantly reduced serum creatinine, interstitial fibrosis in the medulla, and abundance of CD68-positive cells in the cortex and medulla (p <. 05). However, only hPKC(F+) attenuated interstitial fibrosis in the renal cortex and decreased urinary albumin (3.5-fold) and urinary tubular injury marker kidney injury molecule 1 (16-fold). hPKC(F+) also significantly reduced levels of renal cortical monocyte chemotactic protein 1 (1.8-fold) and oxidative DNA marker 8-hydroxy-deoxyguanosine (8-OHdG) (2.4-fold). After 12 weeks, we detected few injected cells, which were localized mostly to the cortical interstitium. Although cell therapy with either hPKC(F+) or hPKC improved renal function, the hPKC(F+) subpopulation provides greater renoprotection, perhaps through attenuation of inflammation and oxidative stress. We conclude that hPKC(F+) may be used as components of cell-based therapies for degenerative kidney diseases.",
keywords = "Adult stem cells, Autologous stem cell transplantation, Cell biology, Cellular therapy, Erythropoietin, Renal fibrosis, Tissue-specific stem cells",
author = "Yamaleyeva, {Liliya M.} and Guimaraes-Souza, {Nadia K.} and Krane, {Louis S.} and Sigrid Agcaoili and Kenneth Gyabaah and Anthony Atala and Tamer Aboushwareb and Yoo, {James J.}",
year = "2012",
month = "12",
day = "1",
doi = "10.5966/sctm.2011-0048",
language = "English",
volume = "1",
pages = "373--383",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury

AU - Yamaleyeva, Liliya M.

AU - Guimaraes-Souza, Nadia K.

AU - Krane, Louis S.

AU - Agcaoili, Sigrid

AU - Gyabaah, Kenneth

AU - Atala, Anthony

AU - Aboushwareb, Tamer

AU - Yoo, James J.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - New therapeutic strategies for chronic kidney disease (CKD) are necessary to offset the rising incidence of CKD and donor shortage. Erythropoietin (EPO), a cytokine produced by fibroblast-like cells in the kidney, has recently emerged as a renoprotective factor with anti-inflammatory, antioxidant properties. This study (a) determined whether human renal cultures (human primary kidney cells [hPKC]) can be enriched in EPO-positive cells (hPKC(F+)) by using magnetic-bead sorting; (b) characterized hPKC(F+) following cell separation; and (c) established that intrarenal delivery of enriched hPKC(F+) cells would be more beneficial in treatment of renal injury, inflammation, and oxidative stress than unsorted hPKC cultures in a chronic kidney injury model. Fluorescence-activated cell sorting analysis revealed higher expression of EPO (36%) and CD73 (27%) in hPKC(F+) as compared with hPKC. After induction of renal injury, intrarenal delivery of hPKC(F+) or hPKC significantly reduced serum creatinine, interstitial fibrosis in the medulla, and abundance of CD68-positive cells in the cortex and medulla (p <. 05). However, only hPKC(F+) attenuated interstitial fibrosis in the renal cortex and decreased urinary albumin (3.5-fold) and urinary tubular injury marker kidney injury molecule 1 (16-fold). hPKC(F+) also significantly reduced levels of renal cortical monocyte chemotactic protein 1 (1.8-fold) and oxidative DNA marker 8-hydroxy-deoxyguanosine (8-OHdG) (2.4-fold). After 12 weeks, we detected few injected cells, which were localized mostly to the cortical interstitium. Although cell therapy with either hPKC(F+) or hPKC improved renal function, the hPKC(F+) subpopulation provides greater renoprotection, perhaps through attenuation of inflammation and oxidative stress. We conclude that hPKC(F+) may be used as components of cell-based therapies for degenerative kidney diseases.

AB - New therapeutic strategies for chronic kidney disease (CKD) are necessary to offset the rising incidence of CKD and donor shortage. Erythropoietin (EPO), a cytokine produced by fibroblast-like cells in the kidney, has recently emerged as a renoprotective factor with anti-inflammatory, antioxidant properties. This study (a) determined whether human renal cultures (human primary kidney cells [hPKC]) can be enriched in EPO-positive cells (hPKC(F+)) by using magnetic-bead sorting; (b) characterized hPKC(F+) following cell separation; and (c) established that intrarenal delivery of enriched hPKC(F+) cells would be more beneficial in treatment of renal injury, inflammation, and oxidative stress than unsorted hPKC cultures in a chronic kidney injury model. Fluorescence-activated cell sorting analysis revealed higher expression of EPO (36%) and CD73 (27%) in hPKC(F+) as compared with hPKC. After induction of renal injury, intrarenal delivery of hPKC(F+) or hPKC significantly reduced serum creatinine, interstitial fibrosis in the medulla, and abundance of CD68-positive cells in the cortex and medulla (p <. 05). However, only hPKC(F+) attenuated interstitial fibrosis in the renal cortex and decreased urinary albumin (3.5-fold) and urinary tubular injury marker kidney injury molecule 1 (16-fold). hPKC(F+) also significantly reduced levels of renal cortical monocyte chemotactic protein 1 (1.8-fold) and oxidative DNA marker 8-hydroxy-deoxyguanosine (8-OHdG) (2.4-fold). After 12 weeks, we detected few injected cells, which were localized mostly to the cortical interstitium. Although cell therapy with either hPKC(F+) or hPKC improved renal function, the hPKC(F+) subpopulation provides greater renoprotection, perhaps through attenuation of inflammation and oxidative stress. We conclude that hPKC(F+) may be used as components of cell-based therapies for degenerative kidney diseases.

KW - Adult stem cells

KW - Autologous stem cell transplantation

KW - Cell biology

KW - Cellular therapy

KW - Erythropoietin

KW - Renal fibrosis

KW - Tissue-specific stem cells

UR - http://www.scopus.com/inward/record.url?scp=84872116231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872116231&partnerID=8YFLogxK

U2 - 10.5966/sctm.2011-0048

DO - 10.5966/sctm.2011-0048

M3 - Article

C2 - 23197816

AN - SCOPUS:84872116231

VL - 1

SP - 373

EP - 383

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 5

ER -